Navigation Links
Savient Pharmaceuticals to Present at the Citi 2011 Global Healthcare Conference
Date:2/17/2011

EAST BRUNSWICK, N.J., Feb. 17, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that John H. Johnson, Chief Executive Officer of Savient will present at the Citi 2011 Global Healthcare Conference on Tuesday, March 1, 2011, at 4:00 p.m. Eastern Time.  The conference will be held at the New York Hilton in New York, NY.  

A live webcast of the presentation can be accessed through the investor relations section of the Company's website www.savient.com.  Following the live presentation, a replay of the webcast will be available on the Company's website for 30 days.

ABOUT SAVIENT PHARMACEUTICALS, INC.

Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA™ (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP").  Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.  Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S.

SVNT - G


'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Savient Pharmaceuticals to Hold Third Quarter 2008 Financial Results Conference Call on Thursday, November 6, 2008
2. Savients Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
3. Savient Submits Biologics License Application (BLA) for pegloticase
4. Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results
5. Savient Pharmaceuticals to Present at the Lazard Capital Markets 5th Annual Healthcare Conference on November 18th
6. Savient Announces Appointment of David Gionco as Chief Financial Officer
7. Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2008 Results Conference Call on Thursday, February 26, 2009
8. Savient Pharmaceuticals to Raise $31 Million Through Registered Direct Offering
9. Savient Pharmaceuticals Reports First Quarter 2009 Financial Results
10. Savient Announces New Date for FDA Arthritis Advisory Panel Review of KRYSTEXXA(TM) for Treatment Failure Gout
11. Savient Provides Update on Meeting with U.S. Food and Drug Administration for KRYSTEXXA(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... The report “Pharmacy Automation Systems Market ... Labeling Systems, Table-top Counters) by End-user (Inpatient Pharmacy ... Trends to 2019” analyzes and studies the major ... Europe, Asia-Pacific, and the Rest of the World ... figures spread through 300 pages and in-depth TOC ...
(Date:10/20/2014)... /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today ... to $5.8 million and provides a good start to Q4.  The ... America and one in the Middle East ... record levels," said Peter Bruijns , President & CEO. "Total ... Q3 than they have been for any complete year since the ...
(Date:10/20/2014)... PLAINSBORO, N.J. (PRWEB) October 20, 2014 ... that the Sidney Kimmel Cancer Center at Thomas ... program. , Through the Strategic Alliance Partnership ... and OncLive will collaborate to raise awareness of ... cancer treatment, and other projects. Clinicians and other ...
(Date:10/19/2014)... OCTOBER 20-22, 2014: The 9th Annual ... take place at the Congress Center Basel, ... now available at http://www.abim.ch . ... from all over the globe will exchange ... products and developments on the world market. ...
Breaking Biology Technology:Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3
... PRXL ), a leading global biopharmaceutical services,organization, ... Goldberg, M.D.,to Chief Operating Officer (COO). Dr. Goldberg ... Perceptive Informatics at,PAREXEL. He will continue to oversee ... von Rickenbach, Chairman and Chief Executive Officer of ...
... Sagent Pharmaceuticals, Inc.,a privately-held specialty pharmaceutical company, today ... USP, and cefuroxime for,injection, USP, two broad spectrum ... Sagent,s ceftriaxone for,injection will be available to the ... single,dose vials, as well as 1g and 2g ...
... PALO ALTO, Calif., July 16 Jazz,Pharmaceuticals, Inc. ... has entered,into definitive agreements with selected investors to ... of (i) one share of the Company,s,common stock, ... (ii) a,warrant to purchase 0.45 of a share ...
Cached Biology Technology:PAREXEL Promotes Dr. Mark A. Goldberg to Chief Operating Officer 2PAREXEL Promotes Dr. Mark A. Goldberg to Chief Operating Officer 3PAREXEL Promotes Dr. Mark A. Goldberg to Chief Operating Officer 4Sagent Pharmaceuticals Launches Ceftriaxone, USP, and Cefuroxime for Injection, USP 2Sagent Pharmaceuticals Launches Ceftriaxone, USP, and Cefuroxime for Injection, USP 3Jazz Pharmaceuticals Announces $26.0 Million Registered Direct Offering 2Jazz Pharmaceuticals Announces $26.0 Million Registered Direct Offering 3
(Date:10/15/2014)... As our ability to assess the pandemic risk from ... developments, we must not allow ourselves to become complacent ... an international consortium of scientists. , Influenza pandemics arise ... have yet to develop widespread immunity – spreads in ... in the past 100 years, the worst of which ...
(Date:10/15/2014)... increased resistance to bacterial pneumonia in female mice to ... , Females are naturally more resistant to respiratory infections ... shown that increased resistance to bacterial pneumonia in female ... 3 (NOS3). They also show that this enzyme is ... hormone estrogen. , The team, lead by Professor Lester ...
(Date:10/14/2014)... thieves, prostate cancer tumors scavenge and hoard copper that ... avarice may be a fatal weakness. , Researchers ... prostate cancer cells by delivering a trove of copper ... cells brimming with the mineral, leaving non-cancer cells healthy. ... commercially available for other uses, could soon be tested ...
Breaking Biology News(10 mins):Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Prostate cancer's penchant for copper may be a fatal flaw 2
... have devised a means of identifying partial, distorted, scratched, ... seconds. Previous techniques have tried to identify a ... match them against a database of templates. The University ... each print and transform the topological pattern into a ...
... issue of G&D, Dr. Guillermo Oliver (St. ... evidence to resolve a century-old debate over the ... development of the lymphatic vasculature is integral to ... and maintaining tissue fluid levels) and disease (lymphedema ...
... Acid rain was one of the worlds worst pollution problems ... Britain, as well as Europe and North America. In ... been acidified, harming fish, stream insects and river birds such ... has been taken across Europe to clean up acid pollutants ...
Cached Biology News:New technology identifies warped fingerprints at warp speed 2Recovery from acid rain 'much slower than expected' 2
Low melting point. Ideally suited for in gel enzymatic reactions. Gelling temp. 24-28C Melting temp. 65C. EEO 0.12 Resolution 0.5-20 kb; Rnase/Dnase: none detected....
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
...
...
Biology Products: